

REMARKS

In the instant application, claims 29-32 and 39-43 are pending and have been made the subject of a Restriction Requirement.

I. Restriction Requirement Under 35 U.S.C. § 121

The Examiner asserts that Restriction to one of the following inventions is required under 35 U.S.C. § 121:


- I. Claims 29-32, and 39 drawn to compounds and compositions of formula (Id), classified in class 548, subclasses 100; 530/531.
- II. Claims 40-43, drawn to method of use of formula (Id), classified in class 514, subclass 18, 19, 360.

See the Office Action, page 2.

To comply with the Examiner's Restriction Requirement, Applicants elect Group I, claims 29-32 and 39.

II. Election of Species

To comply with the Examiner's Election of Species Requirement, Applicants elect the species of the compound of Example 50, ((R,S)-2-((S)-4-(4-(amino-imino-methyl)phenyl)-3-benzyl-4-methyl-2,5-dioximidazolidin-1-yl)-2-(2-methylpropyl)acetyl)-L-aspartyl-L-phenylglycine, having the following chemical structure:



Claims 29-32 and 39 read on the elected species.

Applicants submit that once the compounds of the present invention are found to be novel, then Group II defined by the Examiner where appropriate that would be eligible for rejoinder, pursuant to linking claim practice, should be rejoined.

Applicants also affirm their right to file one or more divisional applications with respect to any other non-elected subject matter.

Respectfully submitted,



Jiang Lin, Reg. No. 51,065
Attorney for Applicants

Date: November 7, 2006

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV1996/F306 US CNT